We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals
JAZZ

454 hedge funds and large institutions have $7.29B invested in Jazz Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 74 funds opening new positions, 136 increasing their positions, 168 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

1.08% more ownership

Funds ownership: 92.94% → 94.02% (+1.1%)

9% more first-time investments, than exits

New positions opened: 74 | Existing positions closed: 68

0% less funds holding

Funds holding: 455 → 454 (-1)

1% less capital invested

Capital invested by funds: $7.39B → $7.29B (-$93.9M)

19% less repeat investments, than reductions

Existing positions increased: 136 | Existing positions reduced: 168

59% less call options, than puts

Call options by funds: $34.2M | Put options by funds: $83.6M

Holders
454
Holders Change
-1
Holders Change %
-0.22%
% of All Funds
6.99%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
74
Increased
136
Reduced
168
Closed
68
Calls
$34.2M
Puts
$83.6M
Net Calls
-$49.5M
Net Calls Change
-$20.7M

Top Buyers

1
Goldman Sachs
Goldman Sachs
New York
+$149M
2
AC
Armistice Capital
New York
+$72.8M
3
Millennium Management
Millennium Management
New York
+$57.9M
4
JP Morgan Chase
JP Morgan Chase
New York
+$42.8M
5
Ameriprise
Ameriprise
Minnesota
+$37M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$194M
2
RG
Redmile Group
California
-$100M
3
PCM
Polaris Capital Management
Massachusetts
-$59.2M
4
AQR Capital Management
AQR Capital Management
Connecticut
-$42.8M
5
Renaissance Technologies
Renaissance Technologies
New York
-$39.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
101
Renaissance Group
Kentucky
$6.84M -$1.89M -14,405 -21%
First Trust Advisors
102
First Trust Advisors
Illinois
$6.83M -$14.5M -110,552 -67%
ERSOT
103
Employees Retirement System of Texas
Texas
$6.74M -$866K -6,590 -11%
SEI Investments
104
SEI Investments
Pennsylvania
$6.7M +$231K +1,755 +3%
Rockefeller Capital Management
105
Rockefeller Capital Management
New York
$6.69M +$3.04M +23,107 +79%
Truist Financial
106
Truist Financial
North Carolina
$6.46M +$1.08M +8,181 +19%
BSA
107
Braun Stacey Associates
New York
$5.97M +$6.16M +46,860 New
Citigroup
108
Citigroup
New York
$5.69M -$4.08M -31,037 -41%
MSV
109
MN Services Vermogensbeheer
Netherlands
$5.67M – – –
HW
110
Hancock Whitney
Mississippi
$5.66M -$138K -1,050 -2%
TPSF
111
Texas Permanent School Fund
Texas
$5.65M -$120K -916 -2%
IBT
112
International Biotechnology Trust
United Kingdom
$5.63M – – –
AB
113
Amalgamated Bank
New York
$5.58M -$201K -1,530 -3%
Los Angeles Capital Management
114
Los Angeles Capital Management
California
$5.53M +$5.7M +43,384 New
Verition Fund Management
115
Verition Fund Management
Connecticut
$5.37M +$1.49M +11,313 +37%
Envestnet Asset Management
116
Envestnet Asset Management
Illinois
$5.19M -$189K -1,438 -3%
RJA
117
Raymond James & Associates
Florida
$5.08M +$176K +1,339 +3%
State of Tennessee, Department of Treasury
118
State of Tennessee, Department of Treasury
Tennessee
$4.66M – – –
VOYA Investment Management
119
VOYA Investment Management
Georgia
$4.47M -$1.43M -10,865 -24%
FAIM
120
Financial Advocates Investment Management
Washington
$4.44M +$1.82M +13,854 New
Hotchkis & Wiley Capital Management
121
Hotchkis & Wiley Capital Management
California
$4.38M -$65.7K -500 -1%
YCM
122
Yousif Capital Management
Michigan
$4.36M +$4.5M +34,241 New
OPERF
123
Oregon Public Employees Retirement Fund
Oregon
$4.36M – – –
State of New Jersey Common Pension Fund D
124
State of New Jersey Common Pension Fund D
New Jersey
$4.31M -$59.3K -451 -1%
FAF
125
Fjarde Ap-fonden
Sweden
$4.17M -$552K -4,200 -11%
3 4
5
6 7

JAZZ Hedge Fund Activity: Q4 2021 in Review

454 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2021, worth a combined $7.29B — down 1.3% from $7.39B a quarter earlier.

Buyers outnumbered sellers: 74 funds opened new JAZZ positions and 68 closed out — a net gain of 6 holders — while 136 added to existing stakes and 168 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $149M. The largest seller was Fidelity Investments, cutting an estimated $194M.

  • 454 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2021, down from 455 in Q3 2021.
  • Funds reported $7.29B of Jazz Pharmaceuticals stock for Q4 2021, down 1.3% quarter-over-quarter.
  • 74 funds opened new Jazz Pharmaceuticals positions in Q4 2021 and 68 closed out, a net change of +6 holders.
  • The largest Jazz Pharmaceuticals buyer in Q4 2021 was Goldman Sachs, an estimated $149M added.
  • The largest Jazz Pharmaceuticals seller in Q4 2021 was Fidelity Investments, an estimated $194M sold.

Based on aggregated 13F filings for Q4 2021.